Diabetes Drug Uses 3-pronged Attack to Reverse Memory Loss in Mice with Alzheimer’s

 Alzheimer’s, neurodegenerative disease, brain cells, brain cell death, brain disease, diabetes drug, memory loss, brain degeneration

The number of people afflicted with Alzheimer’s disease, one of the leading causes of dementia in the UK, is expected to reach at least two million in 30 years. One of the main issues with Alzheimer’s is the lack of new, available treatments. According to researchers, it has been over 15 years since a viable Alzheimer’s treatment has been proposed, lagging severely behind other major diseases. Cross development of drugs that were originally designed to treat other diseases, is a new avenue that must be explore to push the treatment front of Alzheimer’s along. This new ‘triple agonist’ drug, originally developed for diabetes, may be the answer.

What Causes This Buildup of alpha-synuclein and How Does Exercise Slow It

This three-pronged approach to treating Alzheimer’s acts by being an agonist to three different receptors simultaneously: GLP-1/GIP/glucagon. These three receptors are all receptors for growth factors, which have been shown to play a role in impaired brains of Alzheimer’s patients. Mice who were in advanced stages of neurodegeneration were treated with the drug, which caused marked improvements of memory and drug formation by enhancing brain growth factor, reducing amyloid plaques, reducing inflammation, and reducing the rate of nerve cell loss.

Reference

New to the GenScript news page? Feel free to check out our industry-leading Gene Synthesis Service. Or feel free to get a Free Quote today!

Subscribe to Receive Updates
& Promotions From GenScript

* We'll never share your email address with a third-party.

Latest News & Blogs

Find More Gene News